Significance of rs1271572 in the estrogen receptor beta gene promoter and its correlation with breast cancer in a southwestern Chinese population

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Chen, Li ^a   Liang, Yan ^a   Qiu, Juhui ^a   Zhang, Lingling ^a   Chen, Xianchun ^a   Luo, Xiangdong ^a   Jiang, Jun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Chinese; Estrogen receptor beta; Prognosis; SNP

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR BETA; FLUOROURACIL; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YING YANG 1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BINDING KINETICS; BINDING SITE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHINESE; CORRELATION ANALYSIS; DISTANT METASTASIS; FEMALE; FIBROADENOMA; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RECURRENT CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR;

TETRA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; ESTROGEN RECEPTOR BETA; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 84878236943     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-32     Document Type: Article

References (35)

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 2893 2917 10.1002/ijc.25516 21351269
2. Chinese Cancer Registry Annual Report 2009. Chen XY, Kong ZL, Book [Chinese Cancer Registry Annual Report 2009], Press Military Medical Science, 2010 26 28
3. Representativeness of population-based cancer registration in China-comparison of urban and rural areas. Li GL, Chen WQ, Asian Pac J Cancer Prev 2009 10 559 564 19827869
4. A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. Yu KD, Rao NY, Chen AX, Breast Cancer Res Treat 2011 126 37 45 10.1007/s10549-010-0891-2 20390341
5. Identification of a novel estrogen receptor beta1 binding partner, inhibitor of differentiation-1, and role of ERbeta1 in human breast cancer cells. Chen L, Qiu J, Yang C, Cancer Lett 2009 278 210 219 10.1016/j.canlet. 2009.01.008 19217708
6. ERbeta in breast cancer-onlooker, passive player, or active protector? Fox EM, Davis RJ, Shupnik MA, Steroids 2008 73 1039 1051 10.1016/j.steroids. 2008.04.006 18501937
7. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Roger P, Sahla ME, Mäkalä S, Cancer Res 2001 61 2537 2541 11289127 (Pubitemid 32685835)
8. Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility. Treeck O, Elemenler E, Kriener C, J Steroid Biochem Mol Biol 2009 114 207 211 10.1016/j.jsbmb.2009.02.012 19429453
9. Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Maguire P, Margolin S, Skoglund J, Breast Cancer Res Treat 2005 94 145 152 10.1007/s10549-005-7697-7 16261413 (Pubitemid 41547111)
10. Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Gold B, Kalush F, Bergeron J, Cancer Res 2004 64 8891 8900 10.1158/0008-5472.CAN-04-1256 15604249 (Pubitemid 39665494)
11. Polymorphisms in the estrogen receptor beta (ESR2) gene are associated with bone mineral density in Caucasian men and women. Ichikawa S, Koller DL, Peacock M, J Clin Endocrinol Metab 2005 90 5921 5927 10.1210/jc.2004-2253 16118344 (Pubitemid 41606506)
12. Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis-a cohort study. Nilsson M, Dahlman I, Jiao H, BMC Med Genet 2007 8 73 18053221
13. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. Harendza S, Lovett DH, Panzer U, J Biol Chem 2003 278 20490 20499 10.1074/jbc.M211536200 12657623 (Pubitemid 36806345)
14. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Stevens A, Soden J, Brenchley PE, Cancer Res 2003 63 812 816 12591731 (Pubitemid 36231981)
15. The multiple untranslated first exons system of the human estrogen receptor β (ER β) gene. Hirata S, Shoda T, Kato J, J Steroid Biochem Mol Biol 2001 78 33 40 10.1016/S0960-0760(01)00071-1 11530282 (Pubitemid 32791329)
16. Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Zhao C, Lam EW, Sunters A, Oncogene 2003 22 7600 7606 10.1038/sj.onc.1207100 14576822 (Pubitemid 37464093)
17. SNP@Promoter: a database of human SNPs (single nucleotide polymorphisms) within the putative promoter regions. Kim BC, Kim WY, Park D, BMC Bioinforma 2008 1 2 9 Suppl
18. Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Abbas S, Beckmann L, MARIE-GENICA consortium on genetic susceptibility for menopausal hormone therapy related breast cancer risk, Int J Cancer 2010 126 2935 2946 19739075
19. Haplotypes of the estrogen receptor beta gene and breast cancer risk. Cox DG, Bretsky P, Breast and Prostate Cancer Cohort Consortium, Int J Cancer 2008 122 387 392 17935138 (Pubitemid 350234725)
20. Association between single-nucleotide polymorphisms in estrogen receptor beta gene and risk of prostate cancer. Sun YH, Yang B, Wang XH, Zhonghua Wai Ke Za Zhi 2005 43 948 951 16083630
21. Promoting effect of IFN-gamma on the expression of LPS-induced IL-12 p40 and p35 mRNA in murine suppressor macrophages. Qi J, Zhang J, Feng W, Sci China C Life Sci 2000 43 578 588 10.1007/BF02882278 18726352
22. Estrogen receptor polymorphisms: significance to human physiology, disease and therapy. Figtree GA, Noonan JE, Bhindi R, Collins P, Recent Pat DNA Gene Seq 2009 3 164 171 10.2174/187221509789318397 19673701
23. Estrogen receptor mutations in human disease. Herynk MH, Fuqua SA, Endocr Rev 2004 25 869 898 10.1210/er.2003-0010 15583021 (Pubitemid 39657771)
24. Estrogen receptor beta gene polymorphisms and susceptibility to uterine fibroids. Fischer C, Juhasz-Boess I, Lattrich C, Gynecol Endocrinol 2010 26 4 9 10.3109/09513590903159573 19639498
25. Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women. Rexrode KM, Ridker PM, Hegener HH, Clin Chem 2007 53 1749 1756 10.1373/clinchem.2007.091454 17702854 (Pubitemid 47509667)
26. An efficient procedure for genotyping single nucleotide polymorphisms. Ye S, Dhillon S, Xiayi K, Collins AR, Day IN, Nucleic Acids Res 2001 29 88 98 10.1093/nar/29.17.e88
27. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer-a retrospective study. Vinayagam R, Sibson DR, Holcombe C, BMC Cancer 2007 7 131 10.1186/1471-2407-7-131 17640362 (Pubitemid 47307611)
28. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. Lindberg K, Ström A, Lock JG, J Cell Physiol 2010 222 156 167 10.1002/jcp.21932 19780039
29. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Gruvberger-Saal SK, Bendahl PO, Saal LH, Clin Cancer Res 2007 13 1987 1994 10.1158/1078-0432.CCR-06-1823 17404078 (Pubitemid 46649864)
30. Combinatorial biomarker expression in breast cancer. Rakha EA, Reis-Filho JS, Ellis IO, Breast Cancer Res Treat 2010 120 293 308 10.1007/s10549-010-0746- x 20107892
31. Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G, Am J Pathol 2012 180 2120 2133 10.1016/j.ajpath.2012.01.037 22440256
32. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Gordon S, Akopyan G, Garban H, Oncogene 2006 25 1125 1142 10.1038/sj.onc.1209080 16314846
33. YY1 is autoregulated through its own DNA-binding sites. Gordon S, Akopyan G, Garban H, BMC Mol Biol 2009 10 85 10.1186/1471-2199-10-85 19712462
34. The role of YY1 in reduced HP1alpha gene expression in invasive human breast cancer cells. Lieberthal JG, Kaminsky M, Parkhurst CN, Breast Cancer Res 2009 11 42 10.1186/bcr2329 19566924
35. Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. Thomassen M, Tan Q, Kruse TA, BMC Cancer 2008 8 394 10.1186/1471-2407-8-394 19116006